Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P.

Clin Cancer Res. 2018 May 1. doi: 10.1158/1078-0432.CCR-18-0455. [Epub ahead of print]


Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.

Dudal S, Hinton H, Giusti AM, Bacac M, Muller M, Fauti T, Colombetti S, Heckel T, Giroud N, Klein C, Umaña P, Benincosa L, Bachl J, Singer T, Bray-French K.

J Immunother. 2016 Sep;39(7):279-89. doi: 10.1097/CJI.0000000000000132.


CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.

Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg AM, Bröske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Rüttinger D.

Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12.


The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia.

Dallmann R, Weyermann P, Anklin C, Boroff M, Bray-French K, Cardel B, Courdier-Fruh I, Deppe H, Dubach-Powell J, Erb M, Haefeli RH, Henneböhle M, Herzner H, Hufschmid M, Marks DL, Nordhoff S, Papp M, Rummey C, Santos G, Schärer F, Siendt H, Soeberdt M, Sumanovski LT, Terinek M, Mondadori C, Güven N, Feurer A.

J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):163-174. Epub 2011 Aug 28.


Pharmacokinetic evaluation of idebenone.

Becker C, Bray-French K, Drewe J.

Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1437-44. doi: 10.1517/17425255.2010.530656. Review.


Synthesis and structure-activity relationship of N-arylrolipram derivatives as inhibitors of PDE4 isozymes.

Keller TH, Bray-French K, Demnitz FW, Müller T, Pombo-Villar E, Walker C.

Chem Pharm Bull (Tokyo). 2001 Aug;49(8):1009-17.


N-arylrolipram derivatives as potent and selective PDE4 inhibitors.

Bacher E, Boer C, Bray-French K, Demnitz FW, Keller TH, Mazzoni L, Müller T, Walker C.

Bioorg Med Chem Lett. 1998 Nov 17;8(22):3229-34.


Supplemental Content

Loading ...
Support Center